Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



August 2012, Volume 42 Number 8 , p 13 - 13



To prevent thrombotic events, patients in heart failure may receive warfarin or aspirin therapy.1 To determine if warfarin therapy is superior to an aspirin regimen for patients in sinus rhythm who have a reduced left ventricular ejection fraction, researchers followed 2,305 patients for up to 6 years. The primary outcome was the time it took for a patient to experience the first event in a primary, composite end point: ischemic stroke, intracerebral hemorrhage, or death.The rates for primary outcome in the warfarin group were 7.47 events per 100 patient years and 7.93 in the aspirin group, indicating no significant difference in the treatments. The biggest distinction noted was that warfarin reduced the rate of ischemic stroke throughout the follow-up, but warfarin also increased the likelihood of a major hemorrhage. Researchers concluded that the choice between the two drugs should be determined on an individual patient basis.Source: Homma S, Thompson JL, Pullicino PM, et al. Warfarin

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: